![ECOG-ACRIN logo[19516]275×75](https://blog.ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
April 24, 2026
A preview of the upcoming Spring Group Meeting, a recap of AACR 2026, and an update on the current state of the NCI's cancer research efforts
April 24, 2026
This phase 2 trial is evaluating pembrolizumab immunotherapy after surgery in patients with recurrent or second primary head and neck cancer with high-risk features
April 24, 2026
This phase 3 trial seeks to determine if there is any survival benefit from adding a fourth drug to induction therapy—and if so, in which patients
April 24, 2026
The latest clinical trial findings in breast cancer, cancer control and survivorship, health equity, leukemia, melanoma, and NCI-MATCH
April 24, 2026
Timely information about research presented at medical meetings, recognition of research leaders, and more